These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 20072995

  • 1. [Pathogenesis of liver fibrosis: modulation of stellate cells by chemokines].
    Wasmuth HE, Weiskirchen R.
    Z Gastroenterol; 2010 Jan; 48(1):38-45. PubMed ID: 20072995
    [Abstract] [Full Text] [Related]

  • 2. Chemokines in liver inflammation and fibrosis.
    Wasmuth HE, Tacke F, Trautwein C.
    Semin Liver Dis; 2010 Aug; 30(3):215-25. PubMed ID: 20665374
    [Abstract] [Full Text] [Related]

  • 3. Chemokines in hepatitis C virus infection: pathogenesis, prognosis and therapeutics.
    Wald O, Weiss ID, Galun E, Peled A.
    Cytokine; 2007 Jul; 39(1):50-62. PubMed ID: 17629707
    [Abstract] [Full Text] [Related]

  • 4. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.
    Zeremski M, Petrovic LM, Talal AH.
    J Viral Hepat; 2007 Oct; 14(10):675-87. PubMed ID: 17875002
    [Abstract] [Full Text] [Related]

  • 5. Cirrhosis--can we reverse hepatic fibrosis?
    Tangkijvanich P, Yee HF.
    Eur J Surg Suppl; 2002 Oct; (587):100-12. PubMed ID: 16144208
    [Abstract] [Full Text] [Related]

  • 6. Chemokines as immune mediators of liver diseases related to the metabolic syndrome.
    Berres ML, Nellen A, Wasmuth HE.
    Dig Dis; 2010 Oct; 28(1):192-6. PubMed ID: 20460910
    [Abstract] [Full Text] [Related]

  • 7. Increased expression of T cell chemokines and their receptors in chronic hepatitis C: relationship with the histological activity of liver disease.
    Apolinario A, Majano PL, Alvarez-Pérez E, Saez A, Lozano C, Vargas J, García-Monzón C.
    Am J Gastroenterol; 2002 Nov; 97(11):2861-70. PubMed ID: 12425561
    [Abstract] [Full Text] [Related]

  • 8. Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans.
    Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, Scholten D, Berres ML, Zimmermann H, Streetz KL, Tacke F, Hillebrandt S, Schmitz P, Keppeler H, Berg T, Dahl E, Gassler N, Friedman SL, Trautwein C.
    Gastroenterology; 2009 Jul; 137(1):309-19, 319.e1-3. PubMed ID: 19344719
    [Abstract] [Full Text] [Related]

  • 9. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells.
    Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA.
    Hepatology; 2003 May; 37(5):1043-55. PubMed ID: 12717385
    [Abstract] [Full Text] [Related]

  • 10. Chemokines and their receptors in the central nervous system.
    Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G.
    Front Neuroendocrinol; 2001 Jul; 22(3):147-84. PubMed ID: 11456467
    [Abstract] [Full Text] [Related]

  • 11. Chemokine-directed immune cell infiltration in acute and chronic liver disease.
    Karlmark KR, Wasmuth HE, Trautwein C, Tacke F.
    Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):233-42. PubMed ID: 19072358
    [Abstract] [Full Text] [Related]

  • 12. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis.
    van der Poorten D, George J.
    Clin Liver Dis; 2008 Nov; 12(4):805-24, ix. PubMed ID: 18984468
    [Abstract] [Full Text] [Related]

  • 13. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
    Yu X, Huang Y, Collin-Osdoby P, Osdoby P.
    J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
    [Abstract] [Full Text] [Related]

  • 14. CC and CXC chemokine receptors mediate migration, proliferation, and matrix metalloproteinase production by fibroblast-like synoviocytes from rheumatoid arthritis patients.
    García-Vicuña R, Gómez-Gaviro MV, Domínguez-Luis MJ, Pec MK, González-Alvaro I, Alvaro-Gracia JM, Díaz-González F.
    Arthritis Rheum; 2004 Dec; 50(12):3866-77. PubMed ID: 15593223
    [Abstract] [Full Text] [Related]

  • 15. Activated liver stellate cells in chronic viral C hepatitis: histopathological and immunohistochemical study.
    Tomanovic NR, Boricic IV, Brasanac DC, Stojsic ZM, Delic DS, Brmbolic BJ.
    J Gastrointestin Liver Dis; 2009 Jun; 18(2):163-7. PubMed ID: 19565045
    [Abstract] [Full Text] [Related]

  • 16. The relative activity of CXCR3 and CCR5 ligands in T lymphocyte migration: concordant and disparate activities in vitro and in vivo.
    Stanford MM, Issekutz TB.
    J Leukoc Biol; 2003 Nov; 74(5):791-9. PubMed ID: 12960247
    [Abstract] [Full Text] [Related]

  • 17. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications.
    Friedman SL.
    Nat Clin Pract Gastroenterol Hepatol; 2004 Dec; 1(2):98-105. PubMed ID: 16265071
    [Abstract] [Full Text] [Related]

  • 18. Therapeutic potential of chemokine receptor antagonists for liver disease.
    Sahin H, Berres ML, Wasmuth HE.
    Expert Rev Clin Pharmacol; 2011 Jul; 4(4):503-13. PubMed ID: 22114859
    [Abstract] [Full Text] [Related]

  • 19. Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells.
    De Minicis S, Seki E, Oesterreicher C, Schnabl B, Schwabe RF, Brenner DA.
    Hepatology; 2008 Dec; 48(6):2016-26. PubMed ID: 19025999
    [Abstract] [Full Text] [Related]

  • 20. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro.
    Helbig KJ, Ruszkiewicz A, Lanford RE, Berzsenyi MD, Harley HA, McColl SR, Beard MR.
    J Virol; 2009 Jan; 83(2):836-46. PubMed ID: 18987152
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.